Alignment Healthcare, Inc. Common Stock
ALHC
$10.37
-19.86%
Alignment Healthcare, Inc. is a next-generation, consumer-centric healthcare platform that provides Medicare Advantage plans to seniors, marketed and sold direct-to-consumer, combining a proprietary technology platform with a clinical care model to improve health outcomes. The company operates as a challenger in the highly consolidated Medicare Advantage industry, competing against far larger incumbents such as UnitedHealth, Humana, and CVS/Aetna by differentiating on its tech-enabled, high-touch care delivery model. The current investor narrative is dominated by a sharp divergence between improving fundamental execution and deteriorating stock performance: revenue growth has accelerated dramatically (Q4 2025 revenue of $1.01 billion, up 44.4% year-over-year), yet the shares have been under heavy pressure amid margin volatility, a Q4 2025 net loss, and a broader managed care de-rating. Sentiment has also been shaped by the stock's addition to the S&P SmallCap 600 in May 2026 (a liquidity and institutional-ownership positive), a larger-than-expected 2027 Medicare Advantage payment rate increase from CMS in April 2026, and persistent insider selling headlines, including the vice chairman's sale of 25,000 shares in June 2026.…
ALHC
Alignment Healthcare, Inc. Common Stock
$10.37
Related headlines
Investment Opinion: Should I buy ALHC Today?
The synthesized recommendation is a Hold with a speculative bias. The core thesis is that ALHC's 44% revenue growth and deeply discounted PS ratio of 0.99x offer compelling upside, but the lack of consistent profitability and negative free cash flow warrant caution. The analyst consensus average target of $24.08 implies 91% upside, but the wide target range of $16 to $30 and the presence of Neutral ratings from UBS and Barclays indicate low conviction. Investors should wait for clearer signs of margin stabilization before committing capital.
Supporting evidence includes the 44.43% year-over-year revenue growth in Q4 2025, the forward PE of 16.76x (reasonable if earnings materialize), and the PS ratio near historical lows. However, the gross margin of 12.37% is structurally low for managed care, and the Q4 net loss of $11.0 million highlights earnings volatility. The negative free cash flow of $66.6 million in Q4 2025 is a red flag, and the debt-to-equity of 1.84 adds financial risk. The implied upside to the average target is substantial, but the company must prove it can generate sustainable profits.
The biggest risks that could invalidate the thesis are: (1) continued margin compression due to rising medical costs, (2) failure to achieve the consensus EPS of $1.71, and (3) a breakdown below the 52-week low of $12.39, which could trigger further selling. The rating would upgrade to Buy if gross margins stabilize above 12% and free cash flow turns consistently positive, or downgrade to Sell if revenue growth decelerates below 20% or if the company reports another quarterly loss. Relative to its history and peers, the stock appears undervalued on a sales basis but overvalued on book value and EBITDA, reflecting the market's skepticism about its profitability trajectory.
Sign up to view all
ALHC 12-Month Price Forecast
The forward-looking view is cautiously neutral. ALHC's explosive revenue growth and deeply discounted sales multiple provide a compelling long-term opportunity, but the lack of consistent profitability and negative free cash flow create near-term uncertainty. The analyst consensus target of $24.08 implies significant upside, but the wide target range and mixed ratings suggest low conviction. The stock is likely to remain volatile until the company demonstrates sustainable margin expansion. I would upgrade to bullish if Q3 2026 results show gross margin above 12% and positive free cash flow, and downgrade to bearish if revenue growth falls below 20% or if the stock breaks below $12.39.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $24.08 and implied upside of +132.2% versus the current price.
Average Target
$24.08
0 analysts
Implied Upside
+132.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$16 - $30
Analyst target range
Coverage is solid for a small-cap healthcare name, with 13 analysts following ALHC and a consensus average target price of $24.08 — implying roughly +91% upside from the current price of $12.61, an unusually wide gap that signals the sell-side views the recent decline as deeply overdone relative to fundamentals. The recommendation field is listed as "none" in the data, but the institutional ratings history shows a predominantly constructive tilt: JP Morgan upgraded to Overweight in November 2025 and reiterated Overweight in December 2025 and February 2026, TD Cowen and Piper Sandler maintain Buy/Overweight ratings, KeyBanc upgraded to Overweight in August 2025, while UBS and Barclays remain Neutral/Equal Weight. The consensus therefore leans bullish, though the presence of Neutral ratings from major houses indicates the bull case is not unanimous.
The target range spans $16.00 to $30.00 — a low target still implying +27% upside and a high target implying +138% upside — a spread of nearly 2x that signals high uncertainty and low conviction in any single outcome. The $30 high target likely assumes successful margin normalization toward mid-single digits, continued 40%+ revenue growth, and multiple re-rating as the company proves its tech-enabled model can generate sustainable earnings (consistent with the $1.71 consensus EPS estimate); the $16 low target prices in persistent margin compression, elevated medical cost trends, and the risk that growth is achieved at the expense of profitability. Notably, the most recent rating actions (February 2026 JP Morgan Overweight reiteration, January 2026 TD Cowen Buy and Piper Sandler Overweight reiterations) show analysts holding constructive views even as the stock has fallen sharply, suggesting the sell-side sees the decline as sentiment- and flow-driven rather than fundamental — a divergence that, combined with the 3.97-day short ratio, sets up potential for a violent re-rating if the next earnings report confirms margin stabilization.
Bulls vs Bears: ALHC Investment Factors
The bear case currently has stronger evidence due to the stock's severe underperformance, margin volatility, and negative free cash flow, which have driven shares to near 52-week lows. However, the bull case is supported by explosive revenue growth, a deeply discounted PS ratio relative to history, and a wide analyst target gap implying 91% upside. The single most important tension is whether ALHC can convert its rapid revenue growth into sustainable profitability—if margins stabilize in the low-to-mid single digits, the stock could re-rate dramatically; if not, the downtrend may continue. The market is pricing in extreme skepticism, but the divergence between fundamentals and price action suggests a potential inflection point if execution improves.
Bullish
- Explosive revenue growth: Q4 2025 revenue of $1.0128 billion grew 44.43% year-over-year from $701.2 million, far outpacing typical managed care industry growth. This acceleration from $926.9 million in Q1 2025 to $1.0128 billion in Q4 2025 demonstrates strong membership gains and market share capture.
- Deep analyst target upside: The consensus average target price of $24.08 implies roughly 91% upside from the current $12.61, with even the lowest target of $16.00 offering 27% upside. This unusually wide gap suggests the sell-side views the decline as sentiment-driven rather than fundamental.
- Attractive forward valuation: The forward PE of 16.76x is reasonable for a company growing revenue at 44%, and the PS ratio of 0.99x is near the bottom of its historical band (versus 3.86x in Q4 2025 and 5–13x in 2021–2022). This sets up asymmetric upside if margins normalize.
- Positive CMS rate update: A larger-than-expected 2027 Medicare Advantage payment rate increase from CMS in April 2026 boosted sector sentiment and improves revenue visibility. This regulatory tailwind directly benefits ALHC's premium economics.
Bearish
- Severe stock underperformance: The stock is down 37.64% year-to-date and 22.87% over the past year, massively underperforming the S&P 500's +12.08% YTD and +16.22% 1-year returns. Relative strength is deeply negative across all timeframes, including -49.72% YTD versus SPY.
- Thin and volatile margins: Q4 2025 gross margin fell to 10.47% from 12.65% in Q3 2025, and the company swung to a net loss of $11.0 million (EPS -$0.0548) after two profitable quarters. The trailing net margin is essentially breakeven at -0.02%, and operating margin is just 0.37%.
- Negative free cash flow in Q4: Q4 2025 free cash flow was negative $66.6 million with operating cash flow of -$50.4 million, a sharp reversal from Q3 2025's +$160.8 million FCF. This raises concerns about the company's ability to self-fund operations without relying on cash reserves or equity issuance.
- Elevated leverage and valuation multiples: Debt-to-equity stands at 1.84 with total debt to capitalization of 65.3%, and the P/B ratio is 21.81x, far above the 5–12x range of 2021–2024. The EV/EBITDA of 80.85x is also extremely high, reflecting minimal earnings and a stretched balance sheet.
ALHC Technical Analysis
Alignment Healthcare is in a sustained downtrend, with the stock down 22.87% over the past year and 37.64% year-to-date, a stark underperformance versus the S&P 500's +16.22% 1-year and +12.08% YTD returns. At a current price of $12.61, the stock sits just 1.8% above its 52-week low of $12.39 and roughly 49.8% below its 52-week high of $25.12, meaning it is trading at approximately 1.8% of its 52-week range — a positioning that signals capitulation-style weakness rather than a value opportunity, and one that historically precedes either a base-building phase or further breakdown. The maximum drawdown of -48.66% confirms the severity of the decline from peak levels.
Short-term momentum remains decisively negative and is diverging bearishly from an already weak longer-term trend: the stock is down 6.73% over the past month and 36.15% over the past three months, versus a 1-year decline of 22.87%, indicating that the pace of selling has accelerated in recent quarters rather than stabilized. Relative strength is deeply negative across every window — -5.67% over 1 month, -39.19% over 3 months, and -39.09% over 1 year versus SPY — showing persistent, broad-based underperformance rather than a temporary pullback. The most recent sessions show the stock grinding to new lows ($12.61 on 2026-09-11, down 1.18% on the day), with elevated volume of roughly 6.08 million shares and a short ratio of 3.97 days, suggesting short interest is meaningful and could amplify either further downside or a sharp squeeze on any positive catalyst.
Key technical levels are tightly defined: support sits at the 52-week low of $12.39, just $0.22 below the current price, while resistance is anchored at the 52-week high of $25.12 — nearly double the current level. A breakdown below $12.39 would signal a fresh leg lower and likely trigger momentum-driven selling, whereas a reclaim of even the $14–$15 area (the July 2026 breakdown zone) would be the first evidence of stabilization; a move back above $20 would be required to credibly challenge the downtrend. With a beta of 1.113, the stock is roughly 11% more volatile than the market, meaning position sizing should account for above-market drawdown risk, particularly given the -48.66% max drawdown already realized.
Beta
1.11
1.11x market volatility
Max Drawdown
-57.8%
Largest decline past year
52-Week Range
$10-$25
Price range past year
Annual Return
-36.5%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | -25.7% | -2.4% |
| 3m | -51.6% | +2.2% |
| 6m | -42.9% | +14.8% |
| 1y | -36.5% | +14.6% |
| ytd | -48.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Alignment Healthcare's revenue trajectory is genuinely strong and accelerating: Q4 2025 revenue reached $1.0128 billion, up 44.43% year-over-year from $701.2 million in Q4 2024, capping a year in which quarterly revenue rose from $926.9 million in Q1 2025 to $993.7 million in Q3 2025 and $1.0128 billion in Q4 2025. The revenue mix is overwhelmingly driven by health care premium revenue of $425.8 million alongside health care capitation of $33.2 million in the disclosed segment data, underscoring the company's dependence on Medicare Advantage membership growth and per-member premium economics. This growth rate is well above typical managed care industry growth, implying meaningful market-share gains, but the investment case hinges on whether that growth can be converted into durable profitability rather than simply scale.
Profitability remains thin and volatile: Q4 2025 produced a net loss of $11.0 million (EPS -$0.0548) on a gross margin of 10.47%, a deterioration from Q3 2025's net income of $3.7 million (EPS $0.0187) and 12.65% gross margin, and Q2 2025's $15.7 million profit (EPS $0.079) on 13.15% gross margin. The trailing net margin is essentially breakeven at -0.02%, with an operating margin of just 0.37% and a gross margin of 12.37% — levels that are structurally low for the managed care industry, where scale players typically run meaningfully higher margins, reflecting Alignment's subscale position and heavy SG&A load (Q4 2025 SG&A of $125.8 million against $1.0128 billion in revenue). The Q4 swing back to a loss after two profitable quarters illustrates the seasonal and medical-cost sensitivity of the model, and the key question for investors is whether margin can stabilize in the low-to-mid single digits as membership scales.
Balance sheet and cash flow metrics present a mixed picture: the company carries a debt-to-equity ratio of 1.84 (with total debt to capitalization of 65.3% as of Q4 2025), a current ratio of 1.71, and cash of $577.9 million at year-end 2025, providing adequate near-term liquidity. However, Q4 2025 free cash flow was negative $66.6 million with operating cash flow of -$50.4 million, a sharp reversal from Q3 2025's +$160.8 million FCF, reflecting working capital swings and the Q4 loss; trailing twelve-month free cash flow is reported at $123.7 million, and ROE is slightly negative at -0.40% while ROA is 3.07%. The company is not yet reliably self-funding — it depends on cash reserves and modest equity issuance ($15.3 million in Q4 2025) to bridge seasonal working capital gaps — which elevates financial risk if medical cost trends deteriorate.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+44.4%
YoY Comparison
Gross Margin
10.5%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Because Alignment Healthcare's trailing net income is negative (EPS of -$0.00019, trailing PE of -5,337.8x is meaningless), the appropriate primary valuation metric is the price-to-sales ratio, which stands at 0.99x on a trailing basis; the forward PE of 16.76x is the more informative profitability-based metric, implying the market expects a dramatic swing to positive earnings (consensus estimated EPS of $1.71). The enormous gap between the meaningless trailing PE and the reasonable 16.76x forward PE reflects the market pricing in a full transition from breakeven/loss-making to profitable operations, a high-conviction bet on margin normalization that leaves little room for execution error.
On a peer-comparison basis, the 0.99x PS ratio and 0.497x EV/Sales are notably low in absolute terms, but the EV/EBITDA of 80.85x and P/B of 21.81x reveal the tension: the company trades at a steep premium on book value and EBITDA because earnings and equity book value are minimal, while the sales multiple looks cheap only because revenue is large relative to a barely-positive bottom line. Against managed care peers that typically trade at low-single-digit PS multiples with far higher margins, ALHC's discount on sales is arguably justified by its structurally lower gross margin (12.37%) and near-zero net margin, though its 44% revenue growth rate is far superior to the sector — the premium/discount debate ultimately reduces to whether growth or profitability deserves more weight.
Historically, ALHC's own PS ratio has compressed dramatically: it stood at 3.86x in Q4 2025, 3.50x in Q3 2025, 2.73x in Q2 2025, and 3.89x in Q1 2025, versus just 0.99x today — near the bottom of its historical band and well below the 5–13x range seen in 2021–2022. Similarly, the P/B ratio of 21.81x is elevated versus the 5–12x range of 2021–2024, but that is a function of a shrinking equity base rather than multiple expansion. The current sales multiple near historical lows suggests the market is pricing in either significant fundamental deterioration or extreme skepticism about the profitability trajectory — a setup that offers asymmetric upside if margins normalize, but also reflects genuine risk that the growth is being bought at uneconomic prices.
PE
-5337.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
80.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given ALHC's thin margins and negative free cash flow. The company reported a Q4 2025 net loss of $11.0 million and negative free cash flow of $66.6 million, reversing from positive FCF in Q3 2025. With a debt-to-equity ratio of 1.84 and total debt to capitalization of 65.3%, the balance sheet is leveraged, and the current ratio of 1.71 provides only adequate liquidity. Revenue is heavily concentrated in Medicare Advantage premiums, making the company vulnerable to changes in medical cost trends or regulatory shifts. The trailing net margin of -0.02% and operating margin of 0.37% leave little room for error, and any increase in medical utilization could quickly erode profitability.
Market and competitive risks stem from ALHC's subscale position against much larger incumbents like UnitedHealth, Humana, and CVS/Aetna. The stock's beta of 1.113 indicates it is about 11% more volatile than the market, and its -48.66% max drawdown highlights the potential for severe declines. Valuation compression risk is real: the P/B ratio of 21.81x is far above its historical range, and the EV/EBITDA of 80.85x is stretched. Recent news of insider selling, including the vice chairman's sale of 25,000 shares, adds a cautionary signal. Additionally, the broader managed care sector has faced de-rating pressures, and while CMS's 2027 rate increase was positive, it may not be enough to offset competitive and regulatory headwinds.
The worst-case scenario would involve a breakdown below the 52-week low of $12.39, triggered by continued margin deterioration, a miss on earnings expectations, or a broader market selloff. In this scenario, the stock could fall to the analyst low target of $16.00 (which is actually above the current price, but if fundamentals worsen, targets could be revised lower) or even below $10, representing a potential loss of 20-30% from the current price of $12.61. The historical max drawdown of -48.66% from the 52-week high of $25.12 implies a downside to around $12.90, but a break below $12.39 could accelerate selling. Investors could lose 20-35% in a severe adverse scenario, especially if the company fails to achieve the consensus EPS estimate of $1.71.
FAQ
The most severe risk is financial: ALHC has a debt-to-equity ratio of 1.84 and generated negative free cash flow of $66.6 million in Q4 2025, raising concerns about liquidity. Operational risk is high due to thin margins (gross margin of 12.37%) and earnings volatility, with a Q4 net loss of $11.0 million. Competitive risk stems from larger incumbents like UnitedHealth and Humana, which have greater scale and pricing power. Market risk is amplified by a beta of 1.113 and a max drawdown of -48.66%, meaning the stock could fall further if sector sentiment deteriorates.
The 12-month forecast includes three scenarios: a bull case (25% probability) with a target range of $24–$30, a base case (50% probability) with a target range of $16–$22, and a bear case (25% probability) with a target range of $10–$12.39. The base case is most likely, assuming revenue growth remains above 30% but margin improvement is gradual. The key assumption is that gross margin stabilizes around 11–12% and free cash flow turns positive. If the company misses earnings or medical costs rise, the bear case could materialize.
ALHC appears undervalued on a price-to-sales basis, with a PS ratio of 0.99x, near the bottom of its historical range (versus 3.86x in Q4 2025 and 5–13x in 2021–2022). However, it is overvalued on book value (P/B of 21.81x) and EBITDA (EV/EBITDA of 80.85x) due to minimal earnings and a shrinking equity base. The forward PE of 16.76x is reasonable if the company achieves consensus EPS of $1.71, but that requires a dramatic profitability improvement. The market is pricing in significant skepticism about the company's ability to convert growth into earnings.
ALHC presents a high-risk, high-reward opportunity that is not suitable for all investors. The stock trades at $12.61, just 1.8% above its 52-week low, with a consensus target of $24.08 implying 91% upside. However, the company reported a Q4 2025 net loss of $11.0 million and negative free cash flow of $66.6 million, highlighting execution risks. For risk-tolerant investors with a long-term horizon, a small position could be justified if margins stabilize. But conservative investors should wait for clearer signs of profitability before buying.
ALHC is more suitable for long-term investment (minimum 2–3 years) given its early growth stage, high volatility (beta of 1.113), and lack of dividend. The company is investing heavily in growth, which pressures near-term profitability, but the long-term opportunity in Medicare Advantage is substantial. Short-term trading is risky due to the stock's downtrend and potential for further volatility. Investors should have a high risk tolerance and a time horizon that allows for the company to achieve sustainable profitability.